Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned surv... by Gang Fang, Zhipeng Pi, Yiping An, Xinxin Cao, Wei Li, Wei Li, Xiangjun Zhu, Jinxi Ding, Jinxi Ding

Subjects: Get full text

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study by Kei Sonehara, Kazunari Tateishi, Kiyotaka Yoh, Kazuhiro Usui, Yukio Hosomi, Kazuma Kishi, Go Naka, Kageaki Watanabe, Shu Tamano, Kohei Uemura, Hideo Kunitoh

Subjects: Get full text

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial by Enriqueta Felip, David P. Carbone, Martin Reck, Luis Paz-Ares, Yong Yuan, Nan Hu, Niels Reinmuth, Xiaoqing Zhang, Thomas John, Ying Cheng, Shun Lu, Manuel Cobo, Michael Schenker, Tudor-Eliade Ciuleanu, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Eduardo Richardet, Hideaki Mizutani, Bogdan Zurawski, Aurelia Alexandru, Javed Mahmood, Tuli De, Irene Santi, John R. Penrod, Adam Lee

“…We report updated efficacy and safety in all randomized patients with a minimum 4-year follow-up and an exploratory treatment-switching adjustment analysis in all treated patients who received chemotherapy and subsequent immunotherapy.Methods Adults with stage IV/recurrent non-small cell lung cancer (NSCLC), no sensitizing EGFR/ALK alterations, and ECOG performance status ≤1 were randomized 1:1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with chemotherapy (two cycles) or chemotherapy (four cycles, with optional maintenance pemetrexed for the nonsquamous population). …”
Get full text

RETRACTED: Long Noncoding RNA FGD5-AS1 Knockdown Decrease Viability, Migration, and Invasion of Non-Small Cell Lung Cancer (NSCLC) Cells by Regulating the MicroRNA-944/MACC1 Axis by Jian Lv MM, Qinyong Li MM, Ruiqiang Ma MM, Zhen Wang BM, Yingyu Yu MM, Huan Liu BM, Yuanxiu Miao BM, Shujuan Jiang MD

Get full text

One-stage versus two-stage thoracoscopic surgery for synchronous bilateral pulmonary nodules: a propensity score-matched analysis by Yu Han, Fei Xiao, Qianli Ma, Zhenrong Zhang, Zaiyong Wang, Chaoyang Liang, Deruo Liu

Subjects: “…Multiple primary lung cancers…”
Get full text

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis by Huimin Zhao, Shanshan Huang, Jianyu Wu, Yanlan Lu, Yue Zou, Haijian Zeng, Chunlan Li, Jin Wang, Xiaochen Zhang, Xiaochen Zhang, Siliang Duan, Siliang Duan, Weiming Liang

Subjects: Get full text

Severe and Fatal Multilobar Nonclassic Radiation Pneumonitis following Stereotactic Body Radiation Therapy (SBRT) for Treatment of Inoperable Non-Small-Cell Lung Cancer: A Report of Two Cases and Possible Enhancement by Concurrent Amiodarone by Anastasios Georgiou, Adam Farmer

Get full text

NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model by Ismail M Meraz, Mourad Majidi, Renduo Song, Feng Meng, Lihui Gao, Qi Wang, Jing Wang, Elizabeth J Shpall, Jack A Roth

Get full text

Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model by Akihiko Kawahara, Tetsuro Sasada, Koichi Azuma, Hidenobu Ishii, Norikazu Matsuo, Takaaki Tokito, Tomoaki Hoshino, Yohei Miyagi, Huihui Xiang, Tomoyuki Tagami, Rika Kasajima, Yumiko Kato, Sachise Karakawa, Shinya Kikuchi, Akira Imaizumi, Kenta Murotani

“…However, the clinical significance of free amino acids (plasma-free amino acids (PFAAs)) and tryptophan-related metabolites in plasma has not been fully understood in patients with non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors.Methods We conducted a single cohort observational study. …”
Get full text

Gliadin encapsulated PCOs nanoformulation: An effective therapeutic option for metastatic breast cancer by Sant Lal, Monika Kataria, Neeraj Dilbaghi

Subjects: Get full text

BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation: a case report by Yufei Liu, Yufei Liu, Hanhan Lei, Hanhan Lei, Lingling Cai, Lingling Cai, Yuyan Tan, Xinyu Song

Subjects: “…non-small cell lung cancer (NSCLC)…”
Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

Subjects: “…Nonsquamous non-small cell lung cancer…”
Get full text

Glutamine deprivation confers immunotherapy resistance by inhibiting IFN-γ signaling in cancer cells by Zhiwei Yuan, Taiyan Yu, Xu Wang, Kelin Meng, Tianlai Wang, Boyu Wang, Yu Xi, Congjian Wang, Chenxi Zeng, Shaojie Hu, Yitao Tian, Hui Xiong, Qi Wang, Wenbin Zou, Xue Wang, Yi Gao, Xiangning Fu, Lequn Li

Subjects: Get full text

Cannabidiol Vaping–Associated Multifocal NSCLC in a 24-Year-Old Female: A Case Report by Mansi Barthwal, MD, Nataliya Moldovan, MD, Shantanu Banerji, MD, Julian O. Kim, MD

Subjects: Get full text

Colorimetric aptasensor coupled with a deep-learning-powered smartphone app for programmed death ligand-1 expressing extracellular vesicles by Adeel Khan, Adeel Khan, Haroon Khan, Nongyue He, Zhiyang Li, Heba Khalil Alyahya, Yousef A. Bin Jardan

Subjects: Get full text

Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With NSCLC and Brain Metastases: A Systematic Review and Network Meta‐Analysis by Lauren Julia Brown, Nicholas Yeo, Harriet Gee, Benjamin Y. Kong, Eric Hau, Inês Pires daSilva, Adnan Nagrial

Subjects: Get full text

TClC effectively suppresses the growth and metastasis of NSCLC via polypharmacology by Jing Lu, Ying Zhang, Chunyan Yan, Jingwen Liu, Dan Qi, Yue Zhou, Qinwen Wang, Juechen Yang, Jing Jiang, Benhao Wu, Meiling Yang, Weiwei Zhang, Xin Zhang, Xiaoyu Shi, Yan Zhang, Kun Liu, Yongcai Liang, Chaoyang Wang, Hanyu Yang, Yuqing Gao, Yuping Sun, Ronghu Ke, Jason H. Huang, Min Wu, Hongbo Wang, Chunlei Li, Shuang Zhou, Bin Guo, Erxi Wu, Guoying Zhang

Subjects: “…Non-small cell lung cancer…”
Get full text

Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients by Yan-Jei Tang, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu

Subjects: Get full text

Low-exhaustion peripheral circulating γδ T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study by Dongdong Zhang, Guichao Liu, Jinhui Ye, Ke Li, Guojun Zhang, Qiang Quan, Xinhai Zhu, Peng Li

“…Methods Patients with EGFR wild-type (EGFR-WT) or mutant (EGFR-Mut) non-small cell lung cancer (NSCLC), diagnosed between January 2020 and January 2024, were included in this study. …”
Get full text

Lithium-Acetate-Mediated Biginelli One-Pot Multicomponent Synthesis under Solvent-Free Conditions and Cytotoxic Activity against the Human Lung Cancer Cell Line A549 and Breast Cancer Cell Line MCF7 by Harshita Sachdeva, Diksha Dwivedi

“…The prepared compounds are evaluated for anticancer activity against two human cancer cell lines (lung cancer cell line A549 and breast cancer cell line MCF7).…”
Get full text